Antibody-Drug Conjugates Targeting Tumor-Specific Mucin Glycoepitopes

Area of Science:

• Oncology
• Immunology
• Glycobiology

Background:

• Antibody-drug conjugates (ADCs) are crucial for targeted cancer therapy.
• Tumor-specific epitopes are essential for maximizing drug delivery and minimizing side effects.
• Altered glycosylation patterns in cancer create unique glycoepitopes on proteins like mucins.

Purpose of the Study:

• To review glycoepitopes as ideal scaffolds for ADC development.
• To discuss pre-clinical and clinical findings of ADCs targeting mucin-associated glycoepitopes.
• To identify limitations and propose improvements for glycoepitope-targeting ADCs in cancer treatment.

Main Methods:

• Review of literature on glycoepitopes recognized by monoclonal antibodies (mAbs).
• Analysis of pre-clinical and clinical data for ADCs targeting MUC1, Podxl, MUC16, and MUC5AC glycoepitopes.
• Discussion of different glycoepitope types: glycan-only, glycopeptide, and shielded-peptide.

Main Results:

• Glycoepitopes on MUC1, Podxl, MUC16, and MUC5AC are promising targets for ADCs.
• Pre-clinical and clinical studies demonstrate the potential of glycoepitope-targeting ADCs.
• Three distinct types of glycoepitopes (glycan-only, glycopeptide, shielded-peptide) are suitable for mAb recognition.

Conclusions:

• Glycoepitope-targeting ADCs offer a promising strategy for cancer therapy.
• Further research is needed to overcome current limitations and enhance efficacy and specificity.
• Optimizing ADC design and target selection is key for successful clinical translation.